Kiniksa Pharmaceuticals - KNSA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.00
  • Forecasted Upside: 59.30%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$19.46
▲ +0.29 (1.51%)

This chart shows the closing price for KNSA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kiniksa Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KNSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KNSA

Analyst Price Target is $31.00
▲ +59.30% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Kiniksa Pharmaceuticals in the last 3 months. The average price target is $31.00, with a high forecast of $34.00 and a low forecast of $30.00. The average price target represents a 59.30% upside from the last price of $19.46.

This chart shows the closing price for KNSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Kiniksa Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2024Wells Fargo & CompanyInitiated CoverageOverweight$34.00Low
5/1/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$26.00 ➝ $30.00Low
4/24/2024Evercore ISIBoost TargetOutperform ➝ Outperform$25.00 ➝ $30.00Low
4/23/2024WedbushReiterated RatingOutperform$30.00Low
4/2/2024WedbushReiterated RatingOutperform$28.00 ➝ $30.00Low
2/28/2024WedbushReiterated RatingOutperform$28.00Low
1/2/2024WedbushBoost TargetOutperform ➝ Outperform$23.00 ➝ $25.00Low
10/31/2023WedbushReiterated RatingOutperform$23.00Low
3/9/2023JPMorgan Chase & Co.Boost TargetOverweight$19.00 ➝ $20.00Low
3/1/2023WedbushLower Target$26.00 ➝ $20.00Low
12/29/2021Bank of AmericaLower TargetBuy$37.00 ➝ $34.00Medium
11/2/2021The Goldman Sachs GroupReiterated RatingBuy$34.00High
8/4/2021WedbushLower TargetOutperform$32.00 ➝ $24.00High
11/24/2020Evercore ISIInitiated CoverageOutperformHigh
6/30/2020The Goldman Sachs GroupBoost TargetBuy$20.00 ➝ $33.00Medium
6/29/2020Bank of AmericaBoost TargetBuy$25.00 ➝ $40.00High
6/29/2020WedbushBoost Target$30.00 ➝ $38.00High
4/1/2020Bank of AmericaInitiated CoverageBuy$25.00High
3/11/2020JPMorgan Chase & Co.Boost TargetOverweight$22.00 ➝ $24.00High
12/6/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$16.00 ➝ $18.00High
8/14/2019WedbushReiterated RatingBuyHigh
8/14/2019JMP SecuritiesLower TargetMarket Outperform$35.00High
(Data available from 5/24/2019 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/24/2024
  • 13 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/24/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/24/2024

Current Sentiment

  • 8 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Kiniksa Pharmaceuticals logo
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More

Today's Range

Now: $19.46
Low: $19.16
High: $19.52

50 Day Range

MA: $18.91
Low: $16.88
High: $20.33

52 Week Range

Now: $19.46
Low: $13.49
High: $22.09

Volume

41,503 shs

Average Volume

385,875 shs

Market Capitalization

$1.38 billion

P/E Ratio

176.93

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Kiniksa Pharmaceuticals?

The following equities research analysts have issued stock ratings on Kiniksa Pharmaceuticals in the last twelve months: Evercore ISI, JPMorgan Chase & Co., TheStreet, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for KNSA.

What is the current price target for Kiniksa Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Kiniksa Pharmaceuticals in the last year. Their average twelve-month price target is $31.00, suggesting a possible upside of 59.3%. Wells Fargo & Company has the highest price target set, predicting KNSA will reach $34.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $30.00 for Kiniksa Pharmaceuticals in the next year.
View the latest price targets for KNSA.

What is the current consensus analyst rating for Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KNSA will outperform the market and that investors should add to their positions of Kiniksa Pharmaceuticals.
View the latest ratings for KNSA.

What other companies compete with Kiniksa Pharmaceuticals?

How do I contact Kiniksa Pharmaceuticals' investor relations team?

Kiniksa Pharmaceuticals' physical mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company's listed phone number is (781) 431-9100 and its investor relations email address is [email protected]. The official website for Kiniksa Pharmaceuticals is www.kiniksa.com. Learn More about contacing Kiniksa Pharmaceuticals investor relations.